-
Published15/07/2024
-
Deadline19/08/2024
-
Opening of tenders19/08/2024
-
Awarded22/11/2024
-
Today09/04/2026
Utilities
- indicates text translated automatically in your browsing language
CRO (Clinical Research Organisation) as part of the project: Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head to head COMBO-UC trial
The subject of the contract is the service of performing the role of CRO (Clinical Research Organisation) as part of the implemented project: Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head to head COMBO-UC trial, 2022/ABM/03/00013, funded by the Medical Research Agency. A detailed description of the subject of the contract is attached as Annex 2 to the SWZ. The Contractor is obliged to perform the contract on the terms and conditions described in the Model Contract constituting Annex 4 to the SWZ.
https://platformazakupowa.pl/pn/umed_lodz
https://platformazakupowa.pl/pn/umed_lodz
Postal address:
Town: Bydgoszcz
Postal code: 85-092
Country:
Official name: SCIENTIA RESEARCH INSTITUTE Sp. z o.o.
Postal address:
Town: Bydgoszcz
Postal code: 85-092
Country:
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.